Over-expression of MDR1 confers multidrug resistance (MDR) in cancers and remains a major cause for the failure of chemotherapy. In the present study, we found that V-Ets erythroblastosis virus E26 oncogene homolog 2 (ETS2) could activate MDR1 transcription and P-glycoprotein (P-gp) expression in SGC7901 cells. Knockdown of ETS2 attenuated MDR1 transcription and P-gp expression, and increased the sensitivity of MDR cancer cells to cytotoxic drugs that were transported by P-gp in SGC7901/VCR cells. ETS2 could bind to the ETS2 sites on the MDR1 promoter and activate its transcription. The regulation of MDR1 expression by ETS2 may provide potential ways to overcome MDR in cancer treatment.
Introduction
The MDR1 (ABCB1) gene is located on chromosome 7 and consists of 28 exons. Its product P-glycoprotein (P-gp) is the best studied member of the ATP-binding cassette (ABC) family of transporters [1, 2] . P-gp is an efflux pump that is known to confer resistance to a variety of clinically important antineoplastic agents, including doxorubicin, vincristine, taxanes, etoposide, teniposide, and actinomycin D. Many of these agents are used to treat cancers [3, 4] . Over-expression of MDR1 in cancer confers MDR and remains a major cause for the failure of chemotherapy.
Transcription of MDR1 can be induced or repressed by a variety of transcriptional factors. Nuclear transcription factor Y, Sp1 transcription factor and Y box-binding protein I play important roles in the transcriptional activation of the MDR1 gene by genotoxic stress [5] [6] [7] . Histone methyltransferase myeloid/lymphoid or mixed-lineage leukemia 1 (MLL1) increases MDR1 transcription and chemoresistance, while p53 or ubiquitin-like, containing PHD and RING finger domains, 1 (UHRF1) inhibits MDR1 gene transcription and sensitizes cancer cells to anticancer drugs [8] [9] [10] . MyoD or ets variant 4 (PEA3) could bind to the E-box and PEA3 sites on the MDR1 promoter and activate its transcription [11] .
V-Ets erythroblastosis virus E26 oncogene homolog 2 (ETS2) is a transcription factor, and so far, there is no report as to whether ETS2 can regulate MDR1 transcription. The aim of this study was to explore the activity of ETS2 on MDR1 transcription and to reveal the role of ETS2 involved in MDR1-mediated drug resistance, which would be helpful to understand the MDR mechanism.
Materials and Methods

Cell lines and plasmids
The MDR gastric cancer cell line, SGC7901/VCR, and the sensitive cell line, SGC7901, were purchased from Wuhan University Type Culture Collection (Wuhan, China). They were maintained in RPMI 1640 medium (Invitrogen, Carlsbad, USA) containing 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 mg/ml streptomycin at 378C in a humidified atmosphere containing 5% CO 2 and 95% air. For SGC7901/VCR cell line, 0.8 mmol/l of vincristine was added to the medium for the maintenance of the MDR phenotype.
MDR1 promoter/luciferase construct pGL2-MDR1 (21202 to þ118) was kindly provided by Dr Kathleen W. Scotto (Cancer Institute of New Jersey, New Brunswick, USA). ETS2 expression vector was purchased from Origene Company (Rockville, USA).
Reverse transcription-polymerase chain reaction Total RNA was extracted from cells or tissue with TRIzol reagent (Invitrogen). The reverse transcription (RT) reaction was performed using a Superscript First-Strand Synthesis System (Invitrogen). The newly synthesized
cDNA was amplified by polymerase chain reaction (PCR). The reaction mixture contained 2 ml of cDNA template, 1.5 mM MgCl 2 , 2.5 units of Taq polymerase, and 0.5 mM primers. Genes and primers are listed as follows: MDR1, forward primer 5 0 -ATATCAGCAGCCCACATCAT-3 0 , reverse primer 5 0 -GAAGCACTGGGATGTCCGGT-3 0 ; ETS2, forward primer 5 0 -GTGGACCTATTCAGCTGTG G-3 0 , reverse primer 5 0 -TTCCCCGACGTCTTGTGGAT-3 0 . GAPDH was used as an internal control, the primers are as follows: 5 0 -GCCAAAAGGGTCATCATCTC-3 0 and 5 0 -GT AGAGGCAGGGATGATGTTC-3 0 . Amplification cycles were: 948C for 3 min, then 33 cycles at 948C for 1 min, 588C for 1 min, 728C for 1.5 min, followed by 728C for 10 min. Aliquots of PCR product were subject to electrophoresis on 1.5% agarose gels, and PCR fragments were visualized by ethidium bromide staining.
Western blot analysis
Cells were washed twice with phosphate-buffered saline (PBS) containing 1 mM phenylmethylsulphonyl fluoride, and lysed in mammalian protein extraction buffer (Pierce, Rockford, USA). The lysates were transferred to eppendorf tubes and clarified by centrifugation at 12,000 g for 40 min at 48C. Identical amounts (50 mg of protein) of cell lysates were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to nitrocellulose (Millipore, Billerica, USA). The membranes were incubated in blocking solution consisting of 5% powdered non-fat milk in PBST (PBS plus 0.1% Tween 20) at room temperature for 1 h, then immunoblotted with anti-P-gp antibody C219 (1 : 1000; Calbiochem, San Diego, USA), anti-ETS2 antibody (1 : 200; Santa Cruz, Santa Cruz, USA), or anti-GAPDH antibody (1 : 3000; Sigma-Aldrich, St Louis, USA) overnight at 48C, respectively. After being washed three times with Tris-buffered saline and Tween 20 (TBST), the membranes were incubated with horseradish peroxidase-conjugated secondly antibodies for another 1 h followed by three times wash with TBST and then developed by enhanced chemiluminescence detection kit (ECL, Amersham Pharmacia Biotech, Piscataway, USA) according to the manufacturer's instructions.
Small interfering RNA preparation and transfection
The small interfering RNA (siRNA) targeting ETS2 and non-targeting siRNA were purchased from Shanghai GeneChem (Shanghai, China). The target sequence for ETS2 is 5 0 -CAACAGGCUUGGAUUCCAU-3 0 . Cells in the exponential phase of growth were seeded in six-well plates at a concentration of 5 Â 10 5 cells/well. After incubation for 24 h, the cells were transfected with siRNA specific for ETS2 or non-targeting siRNA at a final concentration of 100 nM using oligofectamine and OPTI-MEMI-reduced serum medium (Invitrogen), according to the manufacturer's protocol. Silencing efficiency was examined at 48 h after transfection.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were carried out according to the manufacturer's protocol (Active motif, Carlsbad, USA). Briefly, cells in 150 mm tissue culture dishes were fixed with 1% formaldehyde and incubated for 10 min at 378C. The cells were then washed twice with ice-cold PBS, harvested, and resuspended in ice-cold TNT lysis buffer (20 mM Tris-HCl, pH 7.4, 200 mM NaCl, 1% Triton X-100, 1 mM PMSF, and 1% aprotinin). The lysates were sonicated to shear the DNA to fragments of 200-600 bp, and subjected to immunoprecipitation with ETS2 antibody or IgG (Santa Cruz) as negative control. Three micrograms of antibody was used for each immunoprecipitation. The antibody/protein complexes were collected by Protein G beads and washed three times with ChIP wash buffer (5% SDS, 1 mM EDTA, 0.5% bovine serum albumin and 40 mM NaHPO 4 , pH 7.2). The immune complexes were eluted with 1% SDS and 1 M NaHCO 3 , and the cross-links were reversed by incubation at 658C for 4 h in the presence of 200 mM NaCl and RNase A. The samples were then treated with proteinase K for 2 h, and DNA was purified by mini-column, ethanol precipitation, and resuspended in 100 ml of H 2 O. The primers corresponding to the MDR1 promoter region 2164 and 211 upstream of the transcription start site (sense: 5 0 -CCTCCTGGAAATTCAACCT G-3 0 ; antisense: 5 0 -TGTGGCAAAGAGAGCGAAG-3 0 ) was used for PCR to detect the presence of the MDR1 promoter DNA.
Mutagenesis
MDR1 promoter/luciferase construct pGL2-MDR1 was used as template. The plasmid DNA was methylated with DNA methylase at 378C for 1 h. The plasmid was amplified in a mutagenesis reaction with two overlapping primers, one of which contains the target mutation. The product was linear, double-stranded DNA containing the mutation. The mutagenesis mixture was transformed into wild-type Escherichia coli. The host cells circularized the linear mutated DNA, and McrBC endonuclease in the host cells could digest the methylated template DNA, only leaving the unmethylated and mutated product. For individual mutations, the sequence of ETS2 binding site (ETS2-1, ETS2-2, and ETS2-3) AGGAA was converted to ATATG.
Luciferase reporter gene assay SGC7901 cells were seeded in six-well plates at a density of 1-2 Â 10 5 cells/well and cultured for 24 h. Cells were then co-transfected with wild-type ( pMDR1) or mutants (ETS2 mutant) MDR1 reporter construct (0.5 mg/well) and 0.5 mg of pcDNA3 or ETS2 expression vector, together ETS2 activates MDR1 transcription with 20 ng of control Renilla luciferase reporter construct pRL-TK (Promega, Madison, USA). The total amount of DNA per well was adjusted to 1.5 mg by the addition of sonicated salmon sperm DNA. Luciferase assays were performed as recommended by the vendor (Promega) and normalized relative to protein concentration as determined by the bicinchoninic acid protein assay (Pierce). The promoter activity was then expressed as luminescence units, which is the ratio of luminescence counts of cell lysate and the absorbance at 595 nm for the same amount of cell lysate stained with bicinchoninic acid protein assay reagent.
Drug sensitivity assay SGC7901/VCR cells transfected with ETS2 siRNA or nontargetting siRNA (control siRNA) were plated in 96-well plates in growth medium and incubated at 378C in a humidified 5% CO 2 atmosphere for 60 h in the presence of varying concentrations of vincristine, doxorubicin, paclitaxel, and cisplatin. At the end of incubation, the viability of cells was measured using the MTT assay. Briefly, 20 ml metrizamide (5 mg/ml, Sigma) was added to each well, and the cells were continuously cultured for 4 h. The supernatant was removed and 150 ml dimethyl sulfoxide was added to each well and agitated for 10 min to fully liquefy crystals. Optical density was detected at 490 nm by an automatic enzyme-linked immunosorbent assay (ELISA) reader (Bio-Tek, Burlington, USA).
Statistical analysis
Analysis of variance and Student's t-test were used to determine the statistical significance of differences between experimental groups. P values ,0.05 were considered significant, and the confidence intervals quoted were at the 95% level.
Results
Binding status of ETS2 on the MDR1 promoter between SGC7901 and SGC7901/VCR cells In this study, we found that the MDR1 transcription and P-gp expression were dramatically increased in SGC7901/ VCR cells compared with in SGC7901 cells [ Fig. 1(A,B) ]. In order to determine the potential transcriptional factors binding to the MDR1 promoter, SGC7901 and SGC7901/ VCR cells were subject to ChIP assays. The results demonstrated that ETS2 could bind directly to the transcriptional MDR1 promoter in SGC7901/VCR cells [ Fig. 1(C) ].
Over-expression of ETS2 increases MDR1 transcription and P-gp expression in SGC7901 cells To identify the role of ETS2 in regulating the expression of P-gp, we transfected ETS2 expression vector or control vector into SGC7901 cells, respectively. Figure 2(A) showed that the over-expression of ETS2 could increase MDR1 transcription in SGC7901 cells. Figure 2(B) showed that the over-expression of ETS2 could increase P-gp expression in SGC7901 cells. ChIP results demonstrated that the over-expression of ETS2 increased the presence of ETS2 on the MDR1 promoter [ Fig. 2(C) ].
Effect of ETS2 on the MDR1 promoter activity To identify the role of ETS2 in regulating MDR1 promoter transcription, we co-transfected the MDR1 promoter/luciferase construct pMDR1 with pcDNA3 or ETS2 expression vectors into SGC7901 cells. Figure 3(B) showed that the luciferase activity were enhanced significantly by ETS2, indicating that ETS2 were involved in the activation of the MDR1 promoter activity.
We found four ETS2 sites from -200 to þ1 bp on the MDR1 promoter, as shown in Table 1 and Fig. 3(A) . To determine the potential roles of these ETS2 elements in regulation of MDR1 gene transcription, we individually and combinatorially mutated the three ETS2 sites (ETS2-1, ETS2-2, and ETS2-3) which are close to the transcriptional start site on the MDR1 promoter, and examined ETS2-inducible reporter gene activities in SGC7901 cells. As shown in Fig. 3(C) , any single mutation of three ETS2 sites decreased the reporter gene activity compared with wild-type MDR1 promoter construct. Mutations of any two Figure 1 Binding status of ETS2 on the MDR1 promoter between SGC7901 and SGC7901/VCR cells (A) Relative MDR1 mRNA level was detected in SGC7901 and SGC7901/VCR cells. Total RNA was extracted from the cells, and RT-PCR was performed. (B) P-gp protein level was detected in SGC7901 and SGC7901/VCR cells. Cell lysates were prepared from SGC7901 and SGC7901/VCR cells, and equal amounts (50 mg) of proteins were resolved by SDS-PAGE. P-gp was detected by immunoblotting with anti-P-gp antibody. GAPDH was used as a loading control. (C) Binding status of ETS2 on the MDR1 promoter in SGC7901 and SGC7901/VCR cells. Nucleic extracts were prepared from SGC7901 and SGC7901/VCR cells. ChIP assays were performed using antibody against ETS2. The primers corresponding to the MDR1 promoter region 2164 and 211 upstream of the transcription start site were used for RT-PCR to detect the presence of the MDR1 promoter DNA.
ETS2 activates MDR1 transcription ETS2 sites simultaneously caused a further decrease of reporter gene activity, and the combined mutations of all three ETS2 sites resulted in the maximal decrease of reporter gene activity. These results suggest that all three ETS2 sites contribute in a concerted mechanism to the ETS2-induced transcription of MDR1 gene, and ETS2 can activate MDR1 transcription by binding to a number of ETS2 sites on the MDR1 promoter.
Knockdown of ETS2 attenuates MDR1 expression, presence of ETS2 on the MDR1 promoter SGC7901/VCR cells were treated with 100 nM of ETS2 siRNA or non-targeting siRNA for 48 h. RT-PCR and western blot analysis were performed. As shown in Fig. 4(A,B) , ETS2 siRNA significantly inhibited the expression of ETS2 mRNA and protein in SGC7901/VCR cells after transfection for 48 h. At the same time, we found that knockdown of ETS2 inhibited MDR1 mRNA and P-gp protein significantly. ChIP results demonstrated that knockdown of ETS2 inhibited the presence of ETS2 on the MDR1 promoter [ Fig. 4(C) ].
Knockdown of ETS2 can modulate MDR phenotype
In above studies, we found that ETS2 could bind to ETS2 sites on the MDR1 promoter and activate its transcription, and the over-expression of ETS2 could increase P-gp expression, knockdown of ETS2 could attenuate MDR1 transcription and P-gp expression. We next tested whether knockdown of ETS2 could increase the sensitivity of MDR cancer cells to cytotoxic drugs that were transported by P-gp. SGC7901/VCR cells were transfected with siRNA targeting ETS2 or non-targetting siRNA for 6 h, and then were seeded in 96-well plates and incubated in the presence of various concentrations of doxorubicin, paclitaxel, vincristine or cisplatin for 54 h. As shown in Table 2 , compared with control MDR cells, the sensitivity of MDR cells promoter by ETS2. Luciferase assays were performed as described in 'Materials and Methods' section. *P , 0.05 versus controls. (C) Effects of mutations of ETS2 sites on the MDR1 promoter on ETS2-induced promoter activities in SGC7901 cells. Single or combined mutations of ETS2-1, ETS2-2 and ETS2-3 sites were separately made and luciferase assays were performed as described in 'Materials and Methods' section. n ¼ 3, *P , 0.05 versus controls.
ETS2 activates MDR1 transcription transfected with ETS2 siRNA to doxorubicin, vincristine, and paclitaxel was increased significantly. However, the sensitivity to cisplatin, a drug that is not transported by P-gp, was not affected by silencing of ETS2 expression. As shown in Fig. 5 , the intracellular accumulation of doxorubicin was increased in ETS2-siRNA-treated SGC7901/VCR cells, as compared with that in non-targeting siRNA-treated cells.
Discussion
Erythroblast transformation-specific (ETS) family is a large family with at least 30 members that function as transcription factors. All ETS transcription factors share a highly conserved DNA-binding domain, the ETS domain [12, 13] . ETS2, a member of the ETS family, has been shown to interact with zinc finger, Myleoid, Nervy and DEAF-1 (MYND) domain containing protein 11, cyclin-dependent kinase 10, c-jun, and myb to regulate target gene expression [14] [15] [16] [17] . ETS2 is a proto-oncogene and involved in growth, transformation, and apoptosis. Over-expression of ETS2 can transform primary fibroblasts and induce tumor in the nude mice, which indicated that ETS2 can regulate cell proliferation and transformation [18] [19] [20] . ETS2 activates or represses the transcription of target genes in a contextdependent manner [21] . Elevated expression of ETS2 has been correlated with human breast cancer [22] . ETS2 deletion in tumor-associated macrophages can decrease the frequency and size of lung metastases in three different mouse models of breast cancer metastasis. ETS2 ablation in tumorassociated macrophages can lead to decreased angiogenesis and decrease growth of tumors [23] .
We used SGC7901 and SGC7901/VCR cells in this study. SGC7901/VCR is an established VCR-resistant cell line selected by stepwise exposure of parental SGC7901 cells to increasing concentrations of VCR [24] . Previous reports have proved that P-gp expression is very low in SGC7901 cells, but high in SGC7901/VCR cells. The SGC7901/VCR cell line was 45 times more resistant to VCR than the parental SGC7901 cell line [25] . The SGC7901/VCR cell line has been successfully used as an in vitro MDR reversal model [26] .
In this study, we found that MDR1 expression was low in SGC7901 cells and MDR1 expression was activated in SGC7901/VCR cells, and the presence of ETS2 significantly increased the transcriptional MDR1 promoter in SGC7901/VCR cells. Knockdown of ETS2 could inhibit the presence of ETS2 on the MDR1 promoter region in SGC7901/VCR cells, indicating ETS2 might regulate MDR1 expression. Bioinformatic analysis of the 5 0 -flanking region of the human MDR1 gene showed that there existed four ETS2 sites on the MDR1 promoter region from -200 to þ1 bp, which indicated that ETS2 might bind to MDR1 promoter and regulate MDR1 transcription. Point mutant of ETS2 site in the MDR1 promoter abrogated the activation effect of ETS2 on MDR1 promoter activity, indicating that ETS2 activated MDR1 promoter activity by directly binding to the ETS2 site of MDR1 promoter.
In this study, we also found that the over-expression of ETS2 could increase P-gp expression, knockdown of ETS2 could attenuate MDR1 transcription and P-gp expression, which further confirmed that ETS2 was responsible for P-gp expression. Treatment of MDR cells with ETS2 siRNA enhanced intracellular drug accumulation and the sensitivity of MDR cells to doxorubicin, paclitaxel, and vincristine, but had no effect on the non-P-gp substrate drug, cisplatin. All these data demonstrated that ETS2 could regulate the sensitivity of MDR cells by influencing P-gp expression.
We conclude that ETS2 can activate MDR1 transcription. Knockdown of ETS2 attenuates MDR1 expression and increases the sensitivity of MDR cancer cells to cytotoxic drugs that are transported by P-gp. ETS2 can bind to ETS2 sites on the MDR1 promoter and activate its transcription. These are the first studies to our knowledge to describe that ETS2 activates MDR1 expression and ETS2 is a new gene related to MDR. The elucidation of the role of ETS2 in MDR1 gene transcription might help develop new strategies to inhibit or prevent the induction of MDR1 expression. 
